A randomized open-label Phase II study of letrozole plus afatinib (BIBW2992) versus letrozole alone in first-line treatment of advanced ER+, HER2- postmenopausal breast cancer with low ER expression.
Phase of Trial: Phase II
Latest Information Update: 04 Jan 2019
Price : $35 *
At a glance
- Drugs Afatinib (Primary) ; Letrozole
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Therapeutic Use
- 30 Dec 2018 The study has been completed in Spain, according to European Clinical Trials Database.
- 03 Dec 2018 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated